Arturo Mendoza-Valdés, MD, presented “Prostate Cancer Screening: The Latin American Perspective” during the 29th Annual International Prostate Cancer Update on January 26, 2019 in Beaver Creek, Colorado.

How to cite: Mendoza-Valdés, Arturo “Prostate Cancer Screening: The Latin American Perspective” January 26, 2019. Accessed Nov 2024. https://grandroundsinurology.com/update-on-clinical-trials-of-radium-223/

Prostate Cancer Screening: The Latin American Perspective

Arturo Mendoza-Valdés, MD, provides an update and perspective of treating prostate cancer in Latin America.

Summary:

Arturo Mendoza-Valdés, MD, provides an update and perspective of treating prostate cancer in Latin America. Latin American countries are very heterogeneous regarding their size, population, races, diet, economy, life expectancies, and healthcare problems and systems. The Latin American population is mostly young (60% under 40 in many countries) and includes slightly more women than men. Some of these factors could explain the lower incidence of prostate cancer in these countries compared to that of Europe, USA, or Canada. Due to the variability of these factors, prostate cancer incidence, mortality, and screening in Latin America is also very heterogeneous. Using an internet research platform from the CAU (Confederación Americana de Urología), which unites the urological associations of most of Latin American countries, a survey of screening trends in those countries was performed. Conclusions of this study were as follows:

  • Prostate cancer in Latin America is as heterogeneous as its population. 
  • Prostate cancer incidence in LAM is lower than Europe, USA, and Canada, but is increasing. 
  • Prostate cancer is the number 1 cancer in some countries. 
  • Real epidemiology is unknown. 
  • 75% of PC detected is in advanced stages. 
  • There are no screening policies except in Venezuela. 
  • There are some isolated efforts in individual hospitals, not even in cities or regions. 
  • Screening is unorganized, isolated, and unpublished. 
  • There is no justification for massive screening. 
  • Screening may be done in countries with high or increasing incidence. 
  • What is done most frequently is preventative (education and promotion).  

Dr. Mendoza-Valdés, MD, asserts that urological associations MUST take the lead and get more involved in Latin America.

About the International Prostate Cancer Update

The International Prostate Cancer Update (IPCU) is an annual, multi-day CME conference focused on prostate cancer treatment updates. The conference’s faculty consists of international experts, and the event caters to urologists, medical oncologists, radiation oncologists, and other healthcare professionals. Topics encompass prostate cancer management, from diagnosis to treating advanced and metastatic disease. Dr. Mendoza-Valdés presented this lecture during the 29th IPCU in 2019. Please visit this page in order to learn more about future IPCU meetings.

ABOUT THE AUTHOR

+ posts

Arturo Mendoza-Valdés, MD, attended medical school at the National Autonomous University of Mexico (UNAM) in Mexico City. He completed a residency in urology at the Instituto Nacional de Nutrición “Salvador Zubirán” (INNSZ), also in Mexico City. Dr. Mendoza-Valdés has served as a staff member (1987-2000) and Chief of the Urology Department (1988-1996) at the National Cancer Institute of Mexico. He is currently a Professor in the Urology Residency Program at INNSZ.

Dr. Mendoza-Valdés is a former President of the Mexican Urological Association, as well as a former President of the SCS-AUA. In 1998, he and other Mexican urologists founded the Mexican Urologic Oncology Association, where he served as its President 2001-2003 and has served as Scientific Committee Chairman to this day.

Dr. Mendoza-Valdés has organized 28 International Symposiums of Urologic Oncology in Mexico. He was a member of the scientific committee of the SIU from 1999 to 2013. He is a Co-Founder of the WUOF (World Urologic Oncology Federation) and has been a member of its steering committee since 2004. He has been a member of the Clinical Practice Guidelines of the AUA (2010-2013), and a member of the Urologic Diagnostic and Therapeutic Imaging Committee (2010 to 2016). Dr. Mendoza-Valdés has also been a member of the SUO (Society of Urologic Oncology) since 2013. In 2012, he became Honorary Member of the EAU, and in 2019 Honorary Member of the AUA. He has participated in 3 ICUD panels on prostate cancer and one on penile cancer. He is a member of the editorial board of the CJU. Dr. Mendoza-Valdés has served as faculty at the International Prostate Cancer Update (IPCU) many times.
Arturo Mendoza-Valdés, MD, attended medical school at the National Autonomous University of Mexico (UNAM) in Mexico City. He completed a residency in urology at the Instituto Nacional de Nutrición “Salvador Zubirán” (INNSZ), also in Mexico City. Dr. Mendoza-Valdés has served as a staff member (1987-2000) and Chief of the Urology Department (1988-1996) at the National Cancer Institute of Mexico. He is currently a Professor in the Urology Residency Program at INNSZ.

Dr. Mendoza-Valdés is a former President of the Mexican Urological Association, as well as a former President of the SCS-AUA. In 1998, he and other Mexican urologists founded the Mexican Urologic Oncology Association, where he served as its President 2001-2003 and has served as Scientific Committee Chairman to this day.

Dr. Mendoza-Valdés has organized 28 International Symposiums of Urologic Oncology in Mexico. He was a member of the scientific committee of the SIU from 1999 to 2013. He is a Co-Founder of the WUOF (World Urologic Oncology Federation) and has been a member of its steering committee since 2004. He has been a member of the Clinical Practice Guidelines of the AUA (2010-2013), and a member of the Urologic Diagnostic and Therapeutic Imaging Committee (2010 to 2016). Dr. Mendoza-Valdés has also been a member of the SUO (Society of Urologic Oncology) since 2013. In 2012, he became Honorary Member of the EAU, and in 2019 Honorary Member of the AUA. He has participated in 3 ICUD panels on prostate cancer and one on penile cancer. He is a member of the editorial board of the CJU. Dr. Mendoza-Valdés has served as faculty at the International Prostate Cancer Update (IPCU) many times.